miR-146a rs291064 Identified as Risk Factor for Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

Investigators found an association between miR-146a rs291064 and risk of gastric cancer (GC) development, according to an article published online in the journal European Journal of Cancer Care.

The authors performed a meta-analysis using PubMed and China National Knowledge Infrastructure searches in order to find relevant studies published before July 2014.

In total, seven case-control studies were chosen for the data analysis, including 3,283 cases and 4,535 controls.

Results showed a significant correlation between the genetic polymorphism miR-146a rs291064 and risk of GC under all genetic models (CC vs. GG, OR=0.76, 95% CI: 0.66, 0.87; CC vs. GC+GG, OR=0.84, 95% CI: 0.71, 0.99; CC+GC vs. GG, OR=0.82, 95% CI: 0.73, 0.91).

Furthermore, the authors conducted subgroup analysis by ethnicity and identified an association in Asian that was determined to be statistically significant.

Addition of onartuzumab to paclitaxel with or without bevacizumab did not provide clinical benefit i
Investigators found an association between miR-146a rs291064 and risk of gastric cancer development.
Several studies have investigated the associations between miR-146a rs2910164 and gastric cancer (GC) risk, but results have been inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. PubMed and China National Knowledge Infrastructure searches were carried out for relevant studies published before July 2014.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters